Gene Therapy Using Nanocarriers for Pancreatic Ductal Adenocarcinoma: Applications and Challenges in Cancer Therapeutics
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide, and its incidence is increasing. PDAC often shows resistance to several therapeutic modalities and a higher recurrence rate after surgical treatment in the early localized stage. Combination chemotherapy in advanced...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-01-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/14/1/137 |
| _version_ | 1797491130457128960 |
|---|---|
| author | Eun-Jeong Won Hyeji Park Tae-Jong Yoon Young-Seok Cho |
| author_facet | Eun-Jeong Won Hyeji Park Tae-Jong Yoon Young-Seok Cho |
| author_sort | Eun-Jeong Won |
| collection | DOAJ |
| description | Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide, and its incidence is increasing. PDAC often shows resistance to several therapeutic modalities and a higher recurrence rate after surgical treatment in the early localized stage. Combination chemotherapy in advanced pancreatic cancer has minimal impact on overall survival. RNA interference (RNAi) is a promising tool for regulating target genes to achieve sequence-specific gene silencing. Here, we summarize RNAi-based therapeutics using nanomedicine-based delivery systems that are currently being tested in clinical trials and are being developed for the treatment of PDAC. Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) genome editing has been widely used for the development of cancer models as a genetic screening tool for the identification and validation of therapeutic targets, as well as for potential cancer therapeutics. This review discusses current advances in CRISPR/Cas9 technology and its application to PDAC research. Continued progress in understanding the PDAC tumor microenvironment and nanomedicine-based gene therapy will improve the clinical outcomes of patients with PDAC. |
| first_indexed | 2024-03-10T00:43:02Z |
| format | Article |
| id | doaj.art-4a12491457fc4b32a9c909ad2a0799b3 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-10T00:43:02Z |
| publishDate | 2022-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-4a12491457fc4b32a9c909ad2a0799b32023-11-23T15:04:33ZengMDPI AGPharmaceutics1999-49232022-01-0114113710.3390/pharmaceutics14010137Gene Therapy Using Nanocarriers for Pancreatic Ductal Adenocarcinoma: Applications and Challenges in Cancer TherapeuticsEun-Jeong Won0Hyeji Park1Tae-Jong Yoon2Young-Seok Cho3Laboratory of NanoPharmacy, College of Pharmacy, Research Institute of Pharmaceutical Science and Technology (RIPST), Ajou University, 206 Worldcup-ro, Yeongtong-gu, Suwon 16499, KoreaDivision of Gastroenterology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaLaboratory of NanoPharmacy, College of Pharmacy, Research Institute of Pharmaceutical Science and Technology (RIPST), Ajou University, 206 Worldcup-ro, Yeongtong-gu, Suwon 16499, KoreaDivision of Gastroenterology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaPancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide, and its incidence is increasing. PDAC often shows resistance to several therapeutic modalities and a higher recurrence rate after surgical treatment in the early localized stage. Combination chemotherapy in advanced pancreatic cancer has minimal impact on overall survival. RNA interference (RNAi) is a promising tool for regulating target genes to achieve sequence-specific gene silencing. Here, we summarize RNAi-based therapeutics using nanomedicine-based delivery systems that are currently being tested in clinical trials and are being developed for the treatment of PDAC. Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) genome editing has been widely used for the development of cancer models as a genetic screening tool for the identification and validation of therapeutic targets, as well as for potential cancer therapeutics. This review discusses current advances in CRISPR/Cas9 technology and its application to PDAC research. Continued progress in understanding the PDAC tumor microenvironment and nanomedicine-based gene therapy will improve the clinical outcomes of patients with PDAC.https://www.mdpi.com/1999-4923/14/1/137pancreatic ductal adenocarcinomamiRNAsiRNACRISPR/Cas9nanocarrier |
| spellingShingle | Eun-Jeong Won Hyeji Park Tae-Jong Yoon Young-Seok Cho Gene Therapy Using Nanocarriers for Pancreatic Ductal Adenocarcinoma: Applications and Challenges in Cancer Therapeutics Pharmaceutics pancreatic ductal adenocarcinoma miRNA siRNA CRISPR/Cas9 nanocarrier |
| title | Gene Therapy Using Nanocarriers for Pancreatic Ductal Adenocarcinoma: Applications and Challenges in Cancer Therapeutics |
| title_full | Gene Therapy Using Nanocarriers for Pancreatic Ductal Adenocarcinoma: Applications and Challenges in Cancer Therapeutics |
| title_fullStr | Gene Therapy Using Nanocarriers for Pancreatic Ductal Adenocarcinoma: Applications and Challenges in Cancer Therapeutics |
| title_full_unstemmed | Gene Therapy Using Nanocarriers for Pancreatic Ductal Adenocarcinoma: Applications and Challenges in Cancer Therapeutics |
| title_short | Gene Therapy Using Nanocarriers for Pancreatic Ductal Adenocarcinoma: Applications and Challenges in Cancer Therapeutics |
| title_sort | gene therapy using nanocarriers for pancreatic ductal adenocarcinoma applications and challenges in cancer therapeutics |
| topic | pancreatic ductal adenocarcinoma miRNA siRNA CRISPR/Cas9 nanocarrier |
| url | https://www.mdpi.com/1999-4923/14/1/137 |
| work_keys_str_mv | AT eunjeongwon genetherapyusingnanocarriersforpancreaticductaladenocarcinomaapplicationsandchallengesincancertherapeutics AT hyejipark genetherapyusingnanocarriersforpancreaticductaladenocarcinomaapplicationsandchallengesincancertherapeutics AT taejongyoon genetherapyusingnanocarriersforpancreaticductaladenocarcinomaapplicationsandchallengesincancertherapeutics AT youngseokcho genetherapyusingnanocarriersforpancreaticductaladenocarcinomaapplicationsandchallengesincancertherapeutics |